.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The DREAM trial evaluated mepolizumab, an anti-interleukin-5 monoclonal antibody, in patients with severe eosinophilic asthma. More than 600 participants were randomized to subcutaneous or intravenous mepolizumab at different doses or placebo over one year. Mepolizumab significantly reduced the rate of clinically significant asthma exacerbations, with benefit observed across the studied dosing groups. The trial helped establish eosinophilic inflammation as a therapeutically actionable phenotype and contributed to the broader transition toward biologic therapy for severe asthma. For HCPs, the practical lesson is that biologic treatment begins with correct phenotyping: frequent exacerbations, evidence of type 2 inflammation, steroid burden, and response to optimized inhaled therapy should all be considered. The study does not mean that every patient with an elevated eosinophil count needs a biologic; rather, it supports using biomarkers and clinical history to identify patients in whom targeted treatment is most likely to reduce exacerbations. This evidence maps directly onto the conference’s asthma phenotyping and biologics sessions and its debate on when earlier biologic therapy should be considered.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The DREAM trial evaluated mepolizumab, an anti-interleukin-5 monoclonal antibody, in patients with severe eosinophilic asthma. More than 600 participants were randomized to subcutaneous or intravenous mepolizumab at different doses or placebo over one year. Mepolizumab significantly reduced the rate of clinically significant asthma exacerbations, with benefit observed across the studied dosing groups. The trial helped establish eosinophilic inflammation as a therapeutically actionable phenotype and contributed to the broader transition toward biologic therapy for severe asthma. For HCPs, the practical lesson is that biologic treatment begins with correct phenotyping: frequent exacerbations, evidence of type 2 inflammation, steroid burden, and response to optimized inhaled therapy should all be considered. The study does not mean that every patient with an elevated eosinophil count needs a biologic; rather, it supports using biomarkers and clinical history to identify patients in whom targeted treatment is most likely to reduce exacerbations. This evidence maps directly onto the conference’s asthma phenotyping and biologics sessions and its debate on when earlier biologic therapy should be considered.
3 weeks back
Discover how catalytic nanozymes redefine autoimmune disease therapy by establishing a physiological redox set-point to restore immune tolerance without broad immunosuppression.
Last week
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
A landmark comparative study evaluates atrial electrophysiology across humans, swine, and rodents. By linking cellular recordings with transcriptomics and in silico modeling, researchers resolve cross-species gaps, explaining translational failures to advance targeted therapies for atrial arrhythmias.
3 weeks back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
last month
Researchers have developed an innovative ultrasound-responsive nano-contrast agent that co-delivers CIITA-siRNA and rapamycin directly to inflamed thyroid tissue, significantly reducing autoimmune injury and thyroid autoantibodies in preclinical models of Hashimoto thyroiditis.
3 weeks back
